Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues:
Total revenues	$ 33	$ 213	$ 89	$ 297
Costs and expenses:
Production costs	186	218	394	488
Research and development	1,341	1,106	2,196	2,497
General and administrative	1,733	1,619	3,296	3,283
Total costs and expenses	3,260	2,943	5,886	6,268
Operating loss	(3,227)	(2,730)	(5,797)	(5,971)
Interest and other income	51	21	55	47
Interest expense and other finance costs	(55)	(19)	(194)	(19)
Settlement with vendor	474		474
Redeemable warrants valuation adjustment	362	529	131	923
Gain on sale of building			223
Gain on sale of short term marketable securities	(20)	6	(20)	6
Net loss	(2,415)	(2,193)	(5,128)	(5,014)
Other comprehensive income (loss):
Reclassification adjustments for loss on sales of short term marketable securities included in net loss		(6)		(6)
Unrealized loss on marketable securities	(33)	18	(20)	29
Net comprehensive loss	$ (2,448)	$ (2,181)	$ (5,148)	$ (4,991)
Basic and diluted loss per share	$ (0.05)	$ (0.08)	$ (0.13)	$ (0.19)
Weighted average shares outstanding, basic and diluted	44,673,538	27,306,321	40,494,679	26,329,123
US [Member]
Revenues:
Clinical treatment programs	$ 11	$ 74	$ 24	$ 97
Europe [Member]
Revenues:
Clinical treatment programs	$ 22	$ 139	$ 65	$ 200